Adrenal scintigraphy

Adrenal scintigraphy has been clinically feasible since the development of 131I-19-iodocholesterol in 1970. This agent has been supplanted by the current agent of choice, 6-iodomethyl-19-norcholesterol. Patients receive Lugol's iodine to block the thyroid gland and receive 1–2 mCi of radiochole...

Full description

Saved in:
Bibliographic Details
Published inSeminars in nuclear medicine Vol. 8; no. 1; pp. 23 - 41
Main Authors Thrall, James H., Freitas, John E., Beierwaltes, William H.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 1978
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Adrenal scintigraphy has been clinically feasible since the development of 131I-19-iodocholesterol in 1970. This agent has been supplanted by the current agent of choice, 6-iodomethyl-19-norcholesterol. Patients receive Lugol's iodine to block the thyroid gland and receive 1–2 mCi of radiocholesterol intravenously. Imaging is accomplished 4–7 days postinjection with the gamma camera. Adrenal per cent uptake determinations similar to thyroid uptakes may be accomplished with the aid of a digital computer and standard per cent uptake curves derived from phantom studies. Adrenal suppression scans were developed to enhance differences between the normal and abnormal adrenal cortex in certain clinical conditions. Patients receive dexamethasone prior to radiotracer injection, and serial scans begining 2–3 days postinjection are obtained. In the normal adrenal scintigram, the right adrenal gland is higher than the left and appears slightly hotter. The left adrenal has an oval configuration, while the right adrenal has a truncated or circular configuration in most subjects. Knowledge of the patient's clinical hormonal status is necessary for proper scintigraphic interpretation. With documented glucocorticoid excess, symmetrical visualization is due to adrenal hyperplasia, usually secondary to Cushing's disease. Unilateral visualization indicates the presence of an adenoma or a postsurgical adrenal remnant; and bilateral nonvisualization is typically due to carcinoma. On dexamethasone suppression scans in primary aldosteronism and adrenal androgenism, adenomas demonstrate unilateral or markedly asymmetrical uptake. Patients with micro- and macronodular hyperplasia typically demonstrate bilateral breakthrough in contrast to normal subjects in whom there should be no visualization while on dexamethasone suppression. Distinctly lateralizing suppression scans have a 94% specificity for aldosteronoma and are felt to represent sufficient evidence for this diagnosis that adrenal venous catheterization is not necessary prior to surgery when this pattern is demonstrated. Although the radioiodinated cholesterols do not selectively localize in medullary tissue, adrenal medullary disorders may be diagnosed by inference. Medullary tumors such as pheochromocytoma may displace, distort, or destroy the cortical tissue. Such lesions must be 2 cm in diameter or larger to be detected.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:0001-2998
1558-4623
DOI:10.1016/S0001-2998(78)80005-1